#Glycovax_Pharma
LightNews LightNews
newsen.bsky.social
Glycovax Pharma Launches Affordable CRM197 Protein for Vaccines#Canada#Montreal#Glycovax_Pharma#CRM197#Espoir_Therapeutics
Glycovax Pharma Launches Affordable CRM197 Protein for Vaccines
Glycovax Pharma Inc. begins biomanufacturing of CRM197 protein, aiming to enhance vaccine accessibility for human and animal use.
third-news.com
June 9, 2025 at 1:35 PM
newsen.bsky.social
Glycovax Pharma Announces Strategic Appointments to Fuel Growth and Innovation in Biotechnology#Canada#Montreal#Glycovax_Pharma#Cédric_Héroux#Thierry_Cyr-Lafleur
Glycovax Pharma Announces Strategic Appointments to Fuel Growth and Innovation in Biotechnology
Glycovax Pharma has appointed Cédric Héroux and Thierry Cyr-Lafleur to accelerate operations and commercial development, enhancing its biotechnological prowess.
third-news.com
September 15, 2026 at 1:25 PM
newsen.bsky.social
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections
Glycovax Pharma partners with NRC and Université de Montréal to create a groundbreaking vaccine for Pseudomonas aeruginosa infections, supported by Quebec funding.
third-news.com
October 8, 2025 at 1:47 PM
newsen.bsky.social
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections
Glycovax Pharma has received approval from the National Research Council of Canada to further develop a vaccine targeting deadly Pseudomonas aeruginosa infections.
third-news.com
August 18, 2025 at 1:52 PM